Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Mamatha Patil"'
Publikováno v:
APIK Journal of Internal Medicine, Vol 7, Iss 1, Pp 9-17 (2019)
Background: Microalbuminuria is a marker of cardiovascular diseases and an early event, is a sign of many kidney diseases. This study investigated the prevalence of microalbuminuria in the general population and its determinants. Methods: In this cro
Externí odkaz:
https://doaj.org/article/bc7bc77bd9674f76a675c15cb89012a2
Autor:
Michael Castro, Fabio Iwamoto, Manmeet Ahluwalia, Shahabuddin Usmani, Ansu Kumar, Shweta Kapoor, Rakhi Purushothaman Suseela, Shruthi Kulkarni, Jharana Mohanty, Vijayashree Shyamasundar, Adity Ghosh, Nagendra Prasad, Mamatha Patil, Sayantani Roy Choudhury, Jyoti Chauhan, Mohammed Sauban, Vishwas Joseph, Pallavi Kumari, Upasana Mitra, Anusha Pampana, Humera Azam, Poornachandra G, Annapoorna Prakash, Sayani Basu
Publikováno v:
Neuro-Oncology. 24:vii116-vii117
BACKGROUND TMZ-induced G:T mismatches trigger MMR to perform futile repair of O6-methylguanine leading to apoptosis. Without MMR, the G:T mutation is genomically incorporated to produce DNA mutation signature #11. Hypermutation ensues and may comprom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d29f1c35e5841cab7e506296b2cf128f
https://doi.org/10.1093/neuonc/noac209.441
https://doi.org/10.1093/neuonc/noac209.441
Publikováno v:
Oral and Maxillofacial Surgery for the Clinician ISBN: 9789811513459
Many techniques exist at present for surgical repair of primary cleft lip. Since the introduction of Millard, most of the techniques are based on Millard’s Rotation advancement principle. However, every cleft surgeon aims to modify his/her techniqu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9e2aa23f828096882e8de954e62632e
https://doi.org/10.1007/978-981-15-1346-6_72
https://doi.org/10.1007/978-981-15-1346-6_72
Autor:
Shruthi Kulkarni, Yugandhara Narvekar, Scott C. Howard, Himanshu Grover, Rahul K Raman, Anusha Pampana, Anuj Tyagi, Prashant Ramachandran Nair, Michele Dundas Macpherson, Deepak Anil Lala, S. Mohapatra, Ansu Kumar, Kritika Sahni, Shweta Kapoor, Michael Castro, Nirjhar Mundkur, Vijayashree P Shyamasundar, Ashokraja Balla, Guido Marcucci, Mamatha Patil, Rakhi Purushothaman Suseela, James Christie, Divya Singh, Naga Ganesh Palaniyeppa, Veena Balakrishnan, Sanjana Patel
Publikováno v:
Blood. 138:3690-3690
Background: DNA methyltransferase inhibition (DNMTi) with the hypomethylating agents (HMA) azacitidine (AZA) or decitabine, remains the mainstay of therapy for the majority of high-risk Myelodysplastic Syndromes (MDS) patients. Nevertheless, only 40-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd4abf95e42ad7109ca7566872efd810
https://doi.org/10.1182/blood-2021-153539
https://doi.org/10.1182/blood-2021-153539
Autor:
Mamatha Patil, Naga Ganesh Palaniyeppa, Diwyanshu Sahu, Yashaswini S Ullal, Kabya Basu, Jharana Mohanty, Vishwas Joseph, Upasana Mitra, Scott C. Howard, Mohammed Sauban, Ashokraja Balla, Vijayashree P Shyamasundar, S. Mohapatra, Annapoorna Prakash, Shweta Kapoor, Swati Khandelwal, Guido Marcucci, Liptimayee Behura, Deepak Anil Lala, Michele Dundas Macpherson, Sanjana Patel, Ansu Kumar, Karthik Sundara Raju, Michael Castro, Ashish Kumar Agrawal
Publikováno v:
Blood. 138:3550-3550
Background: Mantle Cell Lymphoma (MCL) accounts for 3-10% of all non-Hodgkin lymphomas with a median overall survival of 3-4 years. Hyper-CVAD (CVAD) with or without Rituximab constitutes first line therapy for treatment of MCL, yet the use of this c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::059d91d4ed7a7e08eac8c4ccd182709f
https://doi.org/10.1182/blood-2021-152423
https://doi.org/10.1182/blood-2021-152423
Autor:
S. Mohapatra, Himanshu Grover, Chandan Kumar, Mamatha Patil, Anish Raju R Amara, Michael Castro, Ansu Kumar, Shruthi Kulkarni, Vamsidhar Velcheti, Annapoorna Prakash, Sayantani Roy Choudhury, Pallavi Kumari, Deepak Anil Lala, Samiksha Avinash Prasad, Nagendra K. Prasad, Rema Mandal, Nirjhar Mundkur, Liptimayee Behura, R. Gopi
Publikováno v:
Journal of Clinical Oncology. 39:e21211-e21211
e21211 Background: Cancer management using cytotoxic drugs is hampered by limited efficacy. Hence, a personalized treatment approach matching chemotherapy with appropriate patients remains a persistent and unmet need in the clinic. Genomic heterogene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9408cf902a2e00fd4d6e5f179605bd03
https://doi.org/10.1200/jco.2021.39.15_suppl.e21211
https://doi.org/10.1200/jco.2021.39.15_suppl.e21211
Publikováno v:
APIK Journal of Internal Medicine, Vol 7, Iss 1, Pp 9-17 (2019)
Background: Microalbuminuria is a marker of cardiovascular diseases and an early event, is a sign of many kidney diseases. This study investigated the prevalence of microalbuminuria in the general population and its determinants. Methods: In this cro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d9f15abf0280622239c5eafbba0a1b0
https://doi.org/10.4103/2666-1802.260271
https://doi.org/10.4103/2666-1802.260271
Autor:
Vojtech Kulvait, Taher Abbasi, Lubomir Minarik, Krishna Kumar Tiwari, Chandan Kumar, Shireen Vali, Karina Vargova, Leylah Drusbosky, Mamatha Patil, Anna Jonasova, Christopher R. Cogle, Rakhi Purushothaman Suseela, Patil Nilesh Dattatraya, Neeraj Kumar Singh, Tomas Stopka
Publikováno v:
Blood. 132:5506-5506
BACKGROUND: TET2 (Ten-eleven-translocation-2) mutations found in 10-30% of MDS and AML patients are actionable for Azacitidine (AZA) treatment (PMID: 21828143). Although response rate of AZA in older AML patients is ~47%, rate of relapse is high due
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7df77a543cfd69c6092a8e20fe730618
https://doi.org/10.1182/blood-2018-99-114466
https://doi.org/10.1182/blood-2018-99-114466
Autor:
Shivgonda C. Birajdar, Ashish Kumar Agrawal, Diwyanshu Sahu, Patrick Y. Wen, Kabya Basu, Manmeet Ahluwalia, Aftab Alam, Shweta Kapoor, S. Mohapatra, Aktar Alam, Drew Watson, Himanshu Grover, Chandan Kumar, Deepak Anil Lala, Rahul K Raman, Preethi Elangovan, Anusha Pampana, Nirjhar Mundkur, Naga Ganesh, Mamatha Patil
Publikováno v:
Web of Science
2519 Background: Despite using cytogenetic and molecular-risk stratification and precision medicine, the current overall outcome of GBM patients remains relatively poor. Therapy selection is often based on information considering only a single aberra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6b2c32b44a3c2e9f8a20f3fd859207e
https://publons.com/wos-op/publon/51356008/
https://publons.com/wos-op/publon/51356008/